# Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC

> **NCT05910034** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 132 (estimated)

## Conditions studied

- Advanced Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Trilaciclib+Envafolimab+Docetaxel
- **DRUG:** Envafolimab+Docetaxel
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05910034
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05910034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05910034, "Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05910034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*